Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale
- PMID: 21855209
- DOI: 10.1016/j.eururo.2011.07.053
Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale
Abstract
Background: Despite widespread adoption of the six-item erectile function (EF) domain of the International Index of Erectile Function (IIEF) as a clinical trial end point, there are currently no objective data on what constitutes a minimal clinically important difference (MCID) in the EF domain.
Objective: Estimate the MCID for the IIEF EF domain.
Design, setting, and participants: Anchor-based MCIDs were estimated using data from 17 randomized, double-blind, placebo-controlled, parallel-group clinical trials of the phosphodiesterase type 5 inhibitor (PDE5-I) tadalafil for 3345 patients treated for 12 wk.
Measurements: The anchor for the MCID is the minimal improvement measure calculated using change from baseline to 12 wk on IIEF question 7: "Over the past 4 weeks, when you attempted sexual intercourse how often was it satisfactory for you?" MCIDs were developed using analysis of variance (ANOVA)- and receiver operating characteristic (ROC)-based methods in a subset of studies (n=11) by comparing patients with and without minimal improvement (n=863). MCIDs were validated in the remaining six studies (n=377).
Results and limitations: The ROC-based MCID for the EF domain was 4, with estimated sensitivity and specificity of 0.74 and 0.73, respectively. MCIDs varied significantly (p<0.0001) according to baseline ED severity (mild: 2; moderate: 5; severe: 7). MCIDs consistently distinguished between patients in the validation sample classified as no change or minimally improved overall and by geographic region, ED etiology, and age group. MCIDs did not differ by age group, geographic region, or ED etiology. Current analyses were based on 17 clinical trials of tadalafil. Results need to be replicated in studies using other PDE5-Is or in nonpharmacologic intervention studies.
Conclusions: The contextualization of treatment-related changes in terms of clinically relevant improvement is essential to understanding treatment efficacy, to interpreting results across studies, and to managing patients effectively. This analysis provides, for the first time, anchor-based estimates of MCIDs in the EF domain score of the IIEF.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Minimal clinically important differences in the erectile function domain: tough and challenging is beautiful.Eur Urol. 2011 Nov;60(5):1017-9. doi: 10.1016/j.eururo.2011.08.043. Epub 2011 Aug 26. Eur Urol. 2011. PMID: 21906865 No abstract available.
-
Re: Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile. Re: Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale.J Urol. 2012 Aug;188(2):547-8. doi: 10.1016/j.juro.2012.03.100. Epub 2012 Jun 15. J Urol. 2012. PMID: 22784747 No abstract available.
Similar articles
-
Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile.J Sex Med. 2012 Jan;9(1):169-79. doi: 10.1111/j.1743-6109.2011.02506.x. Epub 2011 Oct 7. J Sex Med. 2012. PMID: 21981744
-
Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.Eur Urol. 2014 Feb;65(2):455-64. doi: 10.1016/j.eururo.2013.09.037. Epub 2013 Oct 2. Eur Urol. 2014. PMID: 24119319
-
Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.BJU Int. 2004 Oct;94(6):871-7. doi: 10.1111/j.1464-410X.2004.05049.x. BJU Int. 2004. PMID: 15476525 Clinical Trial.
-
Erection hardness: a unifying factor for defining response in the treatment of erectile dysfunction.Urology. 2006 Sep;68(3 Suppl):17-25. doi: 10.1016/j.urology.2006.05.041. Urology. 2006. PMID: 17011372 Review.
-
Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra).Urology. 2006 Sep;68(3 Suppl):26-37. doi: 10.1016/j.urology.2006.06.027. Urology. 2006. PMID: 17011373 Review.
Cited by
-
Platelet-rich plasma therapy in erectile dysfunction and Peyronie's disease: a systematic review of the literature.World J Urol. 2024 May 29;42(1):359. doi: 10.1007/s00345-024-05065-3. World J Urol. 2024. PMID: 38811395 Free PMC article.
-
Effect of Mirabegron in Men With Overactive Bladder and Erectile Dysfunction: A Prospective Observational Study.Cureus. 2024 Apr 13;16(4):e58175. doi: 10.7759/cureus.58175. eCollection 2024 Apr. Cureus. 2024. PMID: 38741834 Free PMC article.
-
Effectiveness of Low-Intensity Extracorporeal Shock Wave Therapy in Erectile Dysfunction: An Analysis of Sexual Function and Penile Hardness at Erection: An Umbrella Review.J Pers Med. 2024 Feb 4;14(2):177. doi: 10.3390/jpm14020177. J Pers Med. 2024. PMID: 38392610 Free PMC article. Review.
-
Cell therapy for male sexual dysfunctions: systematic review and position statements from the European Society for Sexual Medicine.Sex Med. 2024 Feb 9;12(1):qfad071. doi: 10.1093/sexmed/qfad071. eCollection 2024 Feb. Sex Med. 2024. PMID: 38344213 Free PMC article.
-
Testosterone replacement in men with sexual dysfunction.Cochrane Database Syst Rev. 2024 Jan 15;1(1):CD013071. doi: 10.1002/14651858.CD013071.pub2. Cochrane Database Syst Rev. 2024. PMID: 38224135 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous